Biphenotypic acute leukaemia: A case series

Ahmed Aribi, Carlos Bueso-Ramos, Eli Estey, Zeev Estrov, Susan O'Brien, Francis Giles, Stefan Faderl, Deborah Thomas, Partow Kebriaei, Guillermo Garcia-Manero, Sherry Pierce, Jorge Cortes, Hagop Kantarjian, Farhad Ravandi

Research output: Contribution to journalArticle

Abstract

Biphenotypic acute leukaemia (BAL) is a rare type of leukaemia. Whether patients with BAL should be treated with regimens designed for acute myeloid leukaemia (AML), acute lymphocytic leukaemia (ALL) or both remain unclear. We have reviewed the clinical data for 31 BAL patients. Most patients co-expressed B-lymphoid and myeloid markers. No specific chromosomal abnormality was identified. The majority of the patients were treated with regimens devised for treating ALL. Seven patients were treated with regimens designed for AML. Complete remission (CR) rates of 78% and 57% were noted respectively. The overall survival probability at 2 years was 60%.

Original languageEnglish (US)
Pages (from-to)213-216
Number of pages4
JournalBritish Journal of Haematology
Volume138
Issue number2
DOIs
StatePublished - Jul 1 2007
Externally publishedYes

Fingerprint

Biphenotypic Acute Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Chromosome Aberrations
Leukemia
Survival

Keywords

  • Biphenotypic acute leukaemia
  • Diagnosis
  • Immnuophenotype
  • Prognosis
  • Therapy

ASJC Scopus subject areas

  • Hematology

Cite this

Aribi, A., Bueso-Ramos, C., Estey, E., Estrov, Z., O'Brien, S., Giles, F., ... Ravandi, F. (2007). Biphenotypic acute leukaemia: A case series. British Journal of Haematology, 138(2), 213-216. https://doi.org/10.1111/j.1365-2141.2007.06634.x

Biphenotypic acute leukaemia : A case series. / Aribi, Ahmed; Bueso-Ramos, Carlos; Estey, Eli; Estrov, Zeev; O'Brien, Susan; Giles, Francis; Faderl, Stefan; Thomas, Deborah; Kebriaei, Partow; Garcia-Manero, Guillermo; Pierce, Sherry; Cortes, Jorge; Kantarjian, Hagop; Ravandi, Farhad.

In: British Journal of Haematology, Vol. 138, No. 2, 01.07.2007, p. 213-216.

Research output: Contribution to journalArticle

Aribi, A, Bueso-Ramos, C, Estey, E, Estrov, Z, O'Brien, S, Giles, F, Faderl, S, Thomas, D, Kebriaei, P, Garcia-Manero, G, Pierce, S, Cortes, J, Kantarjian, H & Ravandi, F 2007, 'Biphenotypic acute leukaemia: A case series', British Journal of Haematology, vol. 138, no. 2, pp. 213-216. https://doi.org/10.1111/j.1365-2141.2007.06634.x
Aribi A, Bueso-Ramos C, Estey E, Estrov Z, O'Brien S, Giles F et al. Biphenotypic acute leukaemia: A case series. British Journal of Haematology. 2007 Jul 1;138(2):213-216. https://doi.org/10.1111/j.1365-2141.2007.06634.x
Aribi, Ahmed ; Bueso-Ramos, Carlos ; Estey, Eli ; Estrov, Zeev ; O'Brien, Susan ; Giles, Francis ; Faderl, Stefan ; Thomas, Deborah ; Kebriaei, Partow ; Garcia-Manero, Guillermo ; Pierce, Sherry ; Cortes, Jorge ; Kantarjian, Hagop ; Ravandi, Farhad. / Biphenotypic acute leukaemia : A case series. In: British Journal of Haematology. 2007 ; Vol. 138, No. 2. pp. 213-216.
@article{a57a3afc729d4cc68896a4328419710f,
title = "Biphenotypic acute leukaemia: A case series",
abstract = "Biphenotypic acute leukaemia (BAL) is a rare type of leukaemia. Whether patients with BAL should be treated with regimens designed for acute myeloid leukaemia (AML), acute lymphocytic leukaemia (ALL) or both remain unclear. We have reviewed the clinical data for 31 BAL patients. Most patients co-expressed B-lymphoid and myeloid markers. No specific chromosomal abnormality was identified. The majority of the patients were treated with regimens devised for treating ALL. Seven patients were treated with regimens designed for AML. Complete remission (CR) rates of 78{\%} and 57{\%} were noted respectively. The overall survival probability at 2 years was 60{\%}.",
keywords = "Biphenotypic acute leukaemia, Diagnosis, Immnuophenotype, Prognosis, Therapy",
author = "Ahmed Aribi and Carlos Bueso-Ramos and Eli Estey and Zeev Estrov and Susan O'Brien and Francis Giles and Stefan Faderl and Deborah Thomas and Partow Kebriaei and Guillermo Garcia-Manero and Sherry Pierce and Jorge Cortes and Hagop Kantarjian and Farhad Ravandi",
year = "2007",
month = "7",
day = "1",
doi = "10.1111/j.1365-2141.2007.06634.x",
language = "English (US)",
volume = "138",
pages = "213--216",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Biphenotypic acute leukaemia

T2 - A case series

AU - Aribi, Ahmed

AU - Bueso-Ramos, Carlos

AU - Estey, Eli

AU - Estrov, Zeev

AU - O'Brien, Susan

AU - Giles, Francis

AU - Faderl, Stefan

AU - Thomas, Deborah

AU - Kebriaei, Partow

AU - Garcia-Manero, Guillermo

AU - Pierce, Sherry

AU - Cortes, Jorge

AU - Kantarjian, Hagop

AU - Ravandi, Farhad

PY - 2007/7/1

Y1 - 2007/7/1

N2 - Biphenotypic acute leukaemia (BAL) is a rare type of leukaemia. Whether patients with BAL should be treated with regimens designed for acute myeloid leukaemia (AML), acute lymphocytic leukaemia (ALL) or both remain unclear. We have reviewed the clinical data for 31 BAL patients. Most patients co-expressed B-lymphoid and myeloid markers. No specific chromosomal abnormality was identified. The majority of the patients were treated with regimens devised for treating ALL. Seven patients were treated with regimens designed for AML. Complete remission (CR) rates of 78% and 57% were noted respectively. The overall survival probability at 2 years was 60%.

AB - Biphenotypic acute leukaemia (BAL) is a rare type of leukaemia. Whether patients with BAL should be treated with regimens designed for acute myeloid leukaemia (AML), acute lymphocytic leukaemia (ALL) or both remain unclear. We have reviewed the clinical data for 31 BAL patients. Most patients co-expressed B-lymphoid and myeloid markers. No specific chromosomal abnormality was identified. The majority of the patients were treated with regimens devised for treating ALL. Seven patients were treated with regimens designed for AML. Complete remission (CR) rates of 78% and 57% were noted respectively. The overall survival probability at 2 years was 60%.

KW - Biphenotypic acute leukaemia

KW - Diagnosis

KW - Immnuophenotype

KW - Prognosis

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=34250804050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250804050&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2007.06634.x

DO - 10.1111/j.1365-2141.2007.06634.x

M3 - Article

C2 - 17593028

AN - SCOPUS:34250804050

VL - 138

SP - 213

EP - 216

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -